Posted on

PsyBio Therapeutics Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund

PsyBio Therapeutics Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund

OXFORD, Ohio and COCONUT CREEK, Fla., Sept. 17, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel, bespoke, and psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has been included in AdvisorShares Psychedelics Exchange Traded Fund (the “ETF“).

The ETF will actively manage investments in the emerging psychedelic drugs sector, offering exposure to those biotechnology, pharmaceutical and life sciences companies that the ETF sees as leading the industry. The ETF currently includes 16 psychedelics companies and is listed on the NYSE Arca under the ticker symbol (NYSE: PSIL).

Evan Levine, Chief Executive Officer and Chairman of PsyBio, said, “The inclusion of PsyBio in AdvisorShares Psychedelics ETF recognizes us as a leader in the psychedelics industry, as we continue to research and develop innovative treatments to potentially improve mental and neurological health. We want to thank AdvisorShares for this recognition, which is a testament to the work the Company is advancing in this area. We are proud to be included in the ETF and look forward to continuing engagement with investors on the development of PsyBio’s therapeutics program to treat specific clinical conditions.”

Additional information on the AdvisorShares Psychedelics ETF can be found here.

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include, amongst other things, statements regarding the ability of PsyBio to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will file its initial pre-Investigational New Drug (“IND“)  Application request and IND Application within anticipated timeframes; PsyBio will be successful in obtaining IND Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information: Evan Levine, CEO, PsyBio Therapeutics Corp., t: 513.449.9585, e: ir@psybiolife.com; Investor Enquiries: Valter Pinto or Tim Regan, KCSA Strategic Communications, t: 212.896.1254, e: valter@kcsa.com

Posted on

MINDCURE to Participate in Maxim Group LLC’s Advances in Mental Health Virtual Conference

MINDCURE to Participate in Maxim Group LLC’s Advances in Mental Health Virtual Conference

VANCOUVER, BC, Sept. 17 , 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on  September 22, 2021.

Ms. Ramsden will participate in the following panel sessions, The Second Generation – Beyond Psilocybin and MDMA and Delivery, Manufacturing and Technology as part of the virtual panel series ‘Disruptors in the Mental Health Space.’ The panel discussions will be moderated by Dr. Jason McCarthy, Maxim’s Senior Research Analyst covering Healthcare, along with other important voices in the Mental Health industry.

To attend the virtual panels, please register on the M-Vest platform here. For more information about the conference, or to schedule a one-on-one meeting with MINDCURE management, please contact your Maxim representative or KCSA Strategic Communications at mindcure@kcsa.com

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

‍

For further information:

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communication

mindcure@kcsa.com

Posted on

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress

NAPLES, Fla., Sept. 17, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. (“MagicMed”), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction.

With the closing, Enveric intends to expand into a next-generation neuroscience drug discovery platform of novel psychedelics that addresses the large unmet mental health challenges related to CNS indications such as Cancer Related Distress, PTSD, anxiety, depression and pain. Complemented by its existing drug development for both the mind and body, the Company is focused on building a pipeline of novel and proprietary psychedelic assets through its disruptive discovery platform, the Psybrary™.

The Company has appointed Dr. Joseph Tucker, PhD, former CEO of MagicMed, as CEO of Enveric, and David Johnson, former CEO of Enveric, as Executive Chairman.

“Enveric is a biotechnology company with the platform to create intellectual property for the next generation of mental health treatments to fight a global crisis. With both psychedelic derived molecules and cannabinoids, we have a robust pipeline to take us from discovery through clinical development. Our platform has the potential to disrupt and unlock much needed mental health treatments through psychedelic therapies,” commented Dr. Joseph Tucker, incoming CEO of Enveric. “We have brought together pharma and biotech experts with years of experience in bringing innovative treatments to market as well as a discovery team with a world-class biotech laboratory. We are dedicated to our mission to advance the next generation of treatments and look forward to keeping the investment community apprised of our progress.”

“It is my pleasure to welcome Dr. Tucker as Chief Executive Officer of Enveric. From the onset of meeting Dr. Tucker and the MagicMed team, I have been impressed by what they have accomplished, most notably their library of Intellectual Property for Next Generation psychedelic molecules. These assets combined with our existing Enveric pipeline opens the door for multiple treatment opportunities to a large patient population,” said David Johnson, Executive Chairman of Enveric. “I look forward to working closely with the leadership team, as we navigate the exciting prospects in Enveric’s robust pipeline of assets.”

Transaction Details
The transaction is structured as an amalgamation under the Business Corporations Act (British Columbia). At the closing, a recently formed subsidiary of Enveric amalgamated with MagicMed, with the resulting corporation being an indirect wholly owned subsidiary of Enveric. Under the terms of the amalgamation agreement and other related agreements, Enveric issued the shareholders of MagicMed an aggregate of 9,951,237 shares of common stock of Enveric. Following the amalgamation, existing Enveric shareholders own approximately 68.3% of the combined company’s common stock and previous MagicMed shareholders own approximately 31.7% of the combined company’s common stock. Additionally, as part of the closing of the transaction, Enveric received approximately $4 million (CAD) in cash from the MagicMed Treasury.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the synergies and value creation contemplated by the amalgamation; the ability to promptly and effectively integrate MagicMed’s businesses; disruption from the integration of MagicMed making it more difficult to maintain business, contractual and operational relationships; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
ckasunich@kcsa.com / rcona@kcsa.com

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-announces-closing-of-magicmed-industries-acquisition-301379242.html

SOURCE Enveric Biosciences

Posted on

Educated young adults are taking more psychedelics and drinking less: issue 15

Here’s what’s in store for you in today’s issue:

🍄 A different approach to treating depression

🍄 6 stocks to make you $

🍄 Healing racial trauma

🍄 A new psychedelics ETF

🍄 And more.

You’ll want to stay till the end to learn how someone travelled to different dimensions with Post Malone!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast!
How Psilocybin Is Revolutionizing The Way We Die

In this episode Natasha Fearnley, the first nurse to legally experience psilocybin therapy, shares her fascinating views on palliative care.

Therapeutic banner

Can this combination treat depression?

Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.

The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.

Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.

The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).

Healing racial trauma

A mission to end racism, bring equity to healthcare, and treat racial trauma. Psychologist, Monnica Williams of the University of Ottawa, believes that psilocybin and MDMA can help people of colour address the trauma they’ve endured from racial biases.

“Using psychedelics can not only bring these pain points to the surface for healing, but can reduce the anxiety or response to these memories and allow them to speak openly about them without the pain they bring,” Williams says.

She notes that POC are vastly underrepresented in the mental health care sector, specifically in psychedelic-assisted therapy, and expresses the need for specialized training to work with marginalized groups.

Williams has struggled to find funding for her research in this area in the past, but she’s hopeful that her work will gain more traction with the recent increased attention to racial justice.

Tapping into traditional healing

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

inspirational banner

Educated young adults are taking more drugs and drinking less

To escape the boredom and stress of the pandemic, college students are turning to psychedelics and marijuana.

A recent study found that psychedelic drug use among college students nearly doubled during the pandemic, increasing from 5% in 2019 to 9% in 2020. For non-college young adults, use increased from 8% to 10%.

College students also reported record-high marijuana use and record-low levels of alcohol consumption and binge drinking, likely as a result of fewer social events.

Experts predict that these trends reflect need to cope with mental health issues the desire to break monotony with a different mental state.

Psychedelic journalists!

“As the field of psychedelics explodes, we’re going to need sophisticated journalism to provide the public with reliable information and the field with accountability.”

That’s where Tim Ferriss steps in.

His non-profit organization, the Saisei Foundation, just donated $800,000 over three years to UC Berkeley’s Center for the Science of Psychedelics (BCSP) to establish the Ferriss – UC Berkeley Psychedelic Journalism Fellowship.

The fellowship, which will be overseen by BCSP co-founder Michael Pollan, will support young journalists reporting on the psychedelics industry for mainstream news outlets. Journalists can apply to receive grants of up to $15,000 to investigate the science, policy, business and culture of psychedelics.

business banner

These 6 stocks will make you money 🤑

On Tuesday, the Canadian investment bank Eight Capital gave a Buy rating to 6 psychedelic stocks. Here are the projected returns:

Invest in this ETF… because YOLO 😉

New ETF alert!

Yesterday, AdvisorShares launched the first psychedelic ETF on a US exchange – NYSE: PSIL.

The portfolio manager, Dan Ahrens, has an extensive track record of managing ETFs in a variety of sectors including two cannabis ETFs, MSOS and YOLO.

The distribution of holdings is shown below:

legal banner

Michigan paves the way

Michigan could be the next state to decriminalize psilocybin!

Senator Jeff Irwin (D-Ann Arbor) introduced a bill, SB 631, that would decriminalize the use, possession, cultivation, and delivery of psilocybin and mescaline.

The bill would also allow practitioners to use the psychedelics in counseling or spiritual guidance, but commercial sales would remain illegal.

The city of Ann Arbor, Michigan has already decriminalized psychedelics, and Detroit isn’t far behind with a decriminalization initiative to appear on the ballot this November.

Go sign this petition!

A California activist group, Decriminalize California, is working to get a psilocybin legalization measure on the 2022 ballot, and they’re making progress!

The measure, called the California Psilocybin Initiative, would allow the possession, use, cultivation, social sharing, and even the retail sale of psilocybin.

This week, the group was  cleared to begin collecting signatures for the initiative- they’ll need 623,212 registered voters to sign the petition within 180 days. Luckily, 2,800 people have already volunteered to help with the process.

“I feel pretty damn good honestly [about the prospects of the initiative]. People are so psyched for psychedelics,” said the director of the campaign.

Industry Quick Hits

Sept 14 – Nova Mentis (NOVA) Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment Read more…

Sept 14 – First subject dosed in Beckley Psytech’s psilocybin trial for rare headache disorder Read more…

Sept 14 – Mindset Pharma (MSET) Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay Read more…

Sept 17 – Enveric Biosciences (ENVB) Announces Closing of MagicMed Industries Acquisition Read more…

Video of the Week

Expert Answers Psychedelics Questions From Twitter (ft. Michael Pollan)

Seeing aliens with Post Malone

This Reddit user tapped into different dimensions after taking 2.7 grams of Penis Envy mushrooms.

“I turned on a podcast that I highly recommend to all experienced trippers after my experience with it. It was Joe Rogan and Post Malone tripping together. Once I turned on the podcast I was immediately intrigued about how I could feel their emotions and vibes and feel like I was tripping with them. All of the sudden my no-visual trip got slapped in the face when the whole tv starting started to swirl around and their eyes got all geeked out. I was about to turn it off because I didn’t want to have a artificial video of edited psilocybin visuals. I paused the video, and I realized that the screen was still moving like it was before and the visuals were REAL. At that moment in time I got excited because I knew what was about to come was gonna be good.

I turn the podcast back on and I start to zone out at the tv when I feel a rush of euphoria flowing though my body at the beat of my heart. I was manually breathing and I felt like I was gonna fall FORWARD while laying down because the end of my bed was a for some reason interrupted as a cliff my my brain. The whole room was a weird color like a color invert Instagram filter, I don’t know how to explain this in words guys, but I actually felt like I was being lifted and about to be thrown off my bed. I was gripping for dear life my god it was intense.

Then they started taking about aliens.. they said something about them being around all the time but we just can’t see them until we’re on mushrooms. BOOM fucking blast off I was seeing my own version of alien entity’s all around me. Every square inch of my peripheral vision was different species staring at me. It was incredible.

But I’d like to mention, only watch this podcast if you’re experienced because they do talk about ghosts and the most terrifying things they can think of at one point and they actually scared themselves a little bit lol. Creeped me out too because it wasn’t just stories, I FELT the ghosts and spirits. With full force I was like a skipping record player switching through dimensions on every topic they’d talk about and I felt like Post Malone was family for about three hours. I have never been so deep in my life and this is the most excited I’ve ever been about mushrooms and their capabilities of tapping into other worlds and dimensions and having realizations that you can’t EVER have sober.”

Playlist of the Week

Trippy Trance 👽
fishing for a mushroom
Posted on

Blackhawk Growth’s MindBio Therapeutics Plans to Commercialize Intellectual Property Generated from the University of Auckland’s Clinical Trial in Psychedelic Assisted Therapy in Advanced Stage Cancer Patients

Blackhawk Growth’s MindBio Therapeutics Plans to Commercialize Intellectual Property Generated from the University of Auckland’s Clinical Trial in Psychedelic Assisted Therapy in Advanced Stage Cancer Patients

Vancouver, British Columbia – TheNewswire – September 16, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine.

MindBio Therapeutics plans to commercialize the intellectual property generated from the University of Auckland’s clinical trial in psychedelic assisted therapy in advanced-stage cancer patients. The administration of high-dose psychedelic compounds have shown clinically significant benefits in the treatment of psychological distress in advanced cancer patients. However, psychedelics at high doses can vividly alter perceptions; an experience that poses challenges in this vulnerable population. ‘Microdosing’ – repeated administration of psychedelics in low doses does not alter perceptions but may offer similar benefit in reducing anxiety, depression and existential distress. This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted in people who have advanced cancer and anxiety or depression.

Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. The findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, September 16, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, announced today it’s joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.

The company will work with the Digital Therapeutics Alliance focusing on value and reimbursement, policy and regulation, and awareness to educate the broader health care industry about the benefits of including new technologies in current treatment regimes. This framework will shape the way that the myriad of new technologies currently being developed are ultimately adopted and utilized, as well as help clinicians, caregivers, and consumers wade through a flood of options hitting the market.

“Joining the Digital Therapeutics Alliance is a huge opportunity for our company to be at the forefront of how digital technology is adopted and regulated in the mental health industry,” said Kelsey Ramsden, President and CEO of MINDCURE. “We look forward to collaborating with leaders in the space to help define the future as we invest in and research the potential of digital therapeutics, with a focus on psychedelics.”

“We are excited to welcome MINDCURE to the DTA community to help drive advancements in the DTx industry,” said Andy Molnar, CEO of the Digital Therapeutics Alliance. “As our first member headquartered in Canada, their addition expands our global footprint as well as strengthens our coalition of digital therapeutics manufacturers focused on enabling expanded access to safe and effective DTx products to improve mental health care.”

MINDCURE is positioning its software application, iSTRYM, as the industry’s distribution network for science-based, evidence-backed protocols and artificial intelligence data systems. iSTRYM provides data-driven support as it optimizes the healing journey for patients and clinicians — before, during, and after therapy sessions. iSTRYM is built to shift the paradigm of care and access for psychedelic-assisted psychotherapy; reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols.

“Digital therapeutics is the future of mental health care, and there’s a need to balance the fast adoption of new technologies with thoughtful regulation,” said Ramsden. “This partnership solidifies an industry leadership role for the company as we continue to execute on our strategic research and development goals.”

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995

About Digital Therapeutics Alliance

Founded in 2017, the Digital Therapeutics Alliance is a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance provides patients, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products.

Forward-Looking Information

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the timeframe contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information:

Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications mindcure@kcsa.com

Posted on

Tryp Therapeutics To Present At Oppenheimer Fall Healthcare Summit

Tryp Therapeutics To Present At Oppenheimer Fall Healthcare Summit

SAN DIEGO – Sept. 16, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

The conference will be held virtually on September 20-23, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program for chronic pain and other indications.

PRESENTATION DETAILS FOR TRYP THERAPEUTICS

Date: September 21, 2021

Time: 3:35 p.m. EDT

Registration: Contact Oppenheimer at opcoconferences@opco.com to register

The Company has also engaged several corporate communications firms including Edison Group, Digitonic Ltd., Native Ads, Inc., IBN, VLP Inc., and The Dales Report to provide digital media services, marketing, and data analytics services to the Company. The Company plans to allocate approximately CAD$500,000 for such services over an expected four-month period.

 

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:

Joseph Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:

Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

 

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway

Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway

Launches Nordics Regional Expansion

Dr. Lowan Stewart, One of Europe’s Preeminent Ketamine Physicians, Appointed as Awakn’s Regional Director for the Nordics

TORONTO, September 16, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”)), (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest in Axonklinikken AS (“Axon”), a leading ketamine-assisted psychotherapy clinic in Norway. As part of the transaction Axon will be renamed ‘Awakn Oslo AS’, and Axon’s majority shareholder Dr. Lowan Stewart will be appointed as Regional Director for the Nordics and Managing Director Awakn Oslo AS.

The acquisition will enable Awakn to accelerate its clinic roll out program, as Awakn  will now parallel path its regional expansion plans in both the Nordics (Norway, Sweden, Denmark, Finland and Iceland) and U.K. & Ireland, territories with a combined 100m population and US$5trn GDP.

Awakn Oslo AS will serve as a regional hub from which Awakn plans to expand across the Nordics and is in addition to the two other clinics Awakn plans to have operational this fiscal year (Bristol and London locations), all of which Awakn expects to begin generating revenue in the near-term.

“This is a key element of our goal for Awakn to become the leading authority in the development and delivery of psychedelic therapeutics to treat addiction,” said Anthony Tennyson, Awakn’s CEO. “Our approach of development and delivery enables Awakn to earn revenue while we also develop a deep IP portfolio with strong commercial potential. This acquisition will enable Awakn to accelerate the first element of our three-pronged revenue generation strategy: clinics in the UK and Europe, licencing partnership beyond the UK and Europe, and therapeutics commercialisation.”

The new Oslo clinic will be led by Dr. Stewart, one of Europe’s preeminent ketamine physicians. Dr. Stewart was previously the founder and medical director of the Santa Fe Ketamine Clinic, the first ketamine treatment center in New Mexico. He has lectured internationally on ketamine for depression and is a member of the American Society of Ketamine Physicians.

“This marks huge progress for psychedelic-assisted therapies in the Nordic region. As a practicing physician, medical adviser and researcher, I am excited at the opportunity to further expand the use of ketamine-assisted therapies for those suffering from addiction to this region of the world,” said Dr. Stewart. “With its robust pipeline of research, Awakn is poised to address a growing need in our communities for new, research-backed treatment options for a variety of mental illnesses that provide significantly better outcomes.”

As consideration for the acquisition, Awakn shall issue to the shareholders of Axon an aggregate of 200,000 common shares of Awakn at a deemed price of $2.50 per share. Awakn has also agreed to pay to the shareholders of Axon the following additional consideration (the “Additional Consideration”) of up CAD1.35m based on Axon meeting certain milestones:

  • Opening a second clinic in Norway.
  • Opening a first clinic in a second Nordic country.
  • Opening a first clinic in a third Nordic country.
  • Achieving agreed revenue and EBIDTA targets.

Awakn shall have the option to pay any amount of the Additional Consideration in cash or common shares at its option. The value to calculate the number of the common shares to be issued shall be the greater of (i) a 10-day volume weighted average price, (ii) the minimum price allowable by the NEO Exchange, and (iii) CAD$2.50. The initial 200,000 common shares issued shall be subject to a lock-up resulting in 10% being released upon completion of the acquisition and 15% every three months thereafter.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic medicine to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will also deliver evidence backed psychedelic therapies for addiction in clinics in the U.K. and Europe and through licencing partnerships globally.

www.awaknlifesciences.com  |  Twitter  |  LinkedIn  |  Facebook

Notice Regarding Forward Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the acquisition of Axon, the intended business of the Company, the expansion of the Company’s business, generation of revenue. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:

KCSA Strategic Communications

Valter Pinto / Tim Regan

Phone: +1 (212) 896-1254

Awakn@KCSA.com

Media Enquiries:

America and Canada: KCSA Strategic Communications

Anne Donohoe

Adonohoe@KCSA.com

Rest of World: ROAD Communications

Paul Jarman / Anna Ramsey

Awakn@roadcommunications.co.uk

Posted on

NeonMind Appoints Ketamine And Neurostimulation Expert Dr. Roumen Milev, MD, PhD To Specialty Clinic Advisory Board

NeonMind Appoints Ketamine And Neurostimulation Expert Dr. Roumen Milev, MD, PhD To Specialty Clinic Advisory Board

Company Broadens Scientific Expertise with Addition of Mental Health Expert in Setting Up and Managing Interventional Psychiatric Clinics

Vancouver, B.C. – September 16, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today the appointment of Dr. Roumen Milev, MD, PhD, Clinical Lead of Providence Care Hospital Interventional Psychiatry to its Specialty Clinics Advisory Board. Providence Care Hospital is one of Ontario’s leading providers of specialized care in aging, mental health, and rehabilitation and is fully affiliated with Queen’s University and St. Lawrence College, and an esteemed member of the Council of Academic Hospitals of Ontario, Canada.

In his role on NeonMind’s Specialty Clinics Advisory Board, Dr. Milev will leverage his vast experience and success in setting up and managing interventional psychiatry clinics to support NeonMind as it develops its company-branded, specialty clinics network to enhance access to evidence-backed effective treatments including ketamine.

Dr. Milev leads the Interventional Psychiatry Clinic at Providence Care Hospital in Kingston, Ontario and has overseen more than 1,000 patients successfully treated with ketamine and neurostimulation modalities. He was appointed the Clinical Director of the Mood Disorder Research and Treatment Service in Kingston in 2001. From 2007 until 2017, he was the Head of the Department of Psychiatry at Queen’s University. In 2017, he became the Director of Centre for Neuroscience Studies at Queen’s University and in 2018, he was appointed as Vice President, Medical and Academic Affairs at Providence Care Hospital. He is the current Executive Chair Elect of the Canadian Network for Mood and Anxiety Treatments (CANMAT) and an Executive Committee Member of the Canadian Biomarker Integration Network for Depression (CAN-BIND). He is a Fellow of the Royal College of Psychiatrists (UK), a Distinguished Fellow of both the Canadian and American Psychiatry Associations, a Fellow of the Royal College of Physicians of Canada and defended a PhD in Forensic Psychiatry.

Dr. Milev is actively involved in research in depression, bipolar disorder, and other mental disorders with a strong focus on stigma, sleep architecture, psychopharmacological and neurostimulation treatments as well as, microbiome manipulation for treatment of mood and anxiety disorders. He is the author and editor of over 140 peer-reviewed articles and book chapters and has co-authored multiple CANMAT guidelines for management of patients with Major Depressive Disorder and Bipolar Disorders, the world’s most cited mood disorder treatment guidelines as well as CANMAT treatment guidelines including ketamine and neurostimulation.

“Dr. Milev is a global expert in research of novel treatments for mood and anxiety disorders and brings unparalleled experience and leadership expertise in interventional psychiatry which will help support the development and integration of the most successful protocols and treatment modalities for the launch of our specialty clinics. With the addition of Dr. Milev to the clinics board, NeonMind will be well positioned to deliver top notch medical services and programs, bringing access to patients and communities in need,” said Robert Tessarolo, President & CEO of NeonMind.

On the importance of interventional psychiatry, Dr. Milev said, “I am very proud of the work our team at Providence Care is doing to have successfully set up and operated our Interventional Psychiatry which is providing important treatment services to patients using ketamine and neurostimulation modalities. There are many opportunities to expand patients’ access to these highly effective and safe treatments. I am pleased to be working with NeonMind in developing their network of clinics that is focused on enhancing access to treatments and bringing them into community healthcare.”

 

About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

For more information on NeonMind, go to www.NeonMindBiosciences.com

 

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101

 

Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210

 

Media Inquiries:
KCSA Strategic Communications
Annie Graf
neonmind@kcsa.com
Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference

Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference

Vancouver, British Columbia–(Newsfile Corp. – September 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference presented by Maxim Group and hosed by M-Vest taking place Sept. 22, 2021.

The discussion will focus on the topics surrounding Deliver, Manufacturing, & Technology and “What does it take to succeed in Psychedelics beyond drugs and clinics”, beginning at 3:00 P.M. ET on Wednesday, Sept. 22, 2021.

Registration for the event is accessible via https://m-vest.com/events/advances-in-mental-health.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE, NOR ITS REGULATION SERVICES PROVIDER HAVE  REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

info